Increased antifungal drug resistance in clinical isolates of Cryptococcus neoformans in Uganda

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 12, 2015, Pages 7197-7204

  Smith, Kyle D ^a   Achan, Beatrice ^b   Hullsiek, Kathy Huppler ^c   McDonald, Tami R ^d   Okagaki, Laura H ^e   Alhadab, Ali A ^a   Akampurira, Andrew ^b   Rhein, Joshua R ^f   Meya, David B ^b,f   Boulware, David R ^f   Nielsen, Kirsten ^a   Musubire, Abdu ^g   Nabeta, Henry W ^g   Williams, Darlisha A ^g   Morawski, Bozena ^g   Rolfes, Melissa A ^g   Ndyetukira, Jane Francis ^g   Ahimbisibwe, Cynthia ^g   Kugonza, Florence ^g   Sadiq, Alisat ^g   Dyal, Jonathan ^g   Neborak, Julie M ^g   King, Alexa M ^g   Yueh, Nathan ^g   Velamakanni, Sruti S ^g   Namudde, Alice ^g   Kandole, Tadeo Kiiza ^g   Kaboggoza, Julian ^g   Laker, Eva ^g   Luggya, Tony ^g   Tugume, Liliane ^g   Abassi, Mahsa ^g   Birkenkamp, Kate ^g   Butler, Elissa K ^g   Fujita, A Wendy ^g   Halupnick, Ryan ^g   Strain, Anna K ^g   Vedula, Priya ^g   Rajasingham, Radha ^g   Kambugu, Andrew ^g   Bohjanen, Paul R ^g   more..

^a UNIVERSITY OF MINNESOTA   (United States)

^b MAKERERE UNIVERSITY   (Uganda)

^c UNIVERSITY OF MINNESOTA   (United States)

^d ST CATHERINE UNIVERSITY   (United States)

^e NORTH CAROLINA STATE UNIVERSITY   (United States)

^f UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^g NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; ANTIGEN; AZOLE FUNGICIDE; FLUCONAZOLE; FUNGICIDE; SERTRALINE; UNCLASSIFIED DRUG;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BROTH DILUTION; COMPARATIVE STUDY; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCUS NEOFORMANS; DRUG DETERMINATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MULTILOCUS SEQUENCE TYPING; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; UGANDA; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG EFFECTS; FEMALE; GENETICS; GROWTH, DEVELOPMENT AND AGING; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOLOGY; ISOLATION AND PURIFICATION; MALE; MENINGITIS, CRYPTOCOCCAL; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIXED INFECTION; TREATMENT OUTCOME; VIROLOGY;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; COINFECTION; CRYPTOCOCCUS NEOFORMANS; DRUG RESISTANCE, FUNGAL; DRUG THERAPY, COMBINATION; FEMALE; FLUCONAZOLE; HIV; HIV INFECTIONS; HUMANS; MALE; MENINGITIS, CRYPTOCOCCAL; MICROBIAL SENSITIVITY TESTS; MULTILOCUS SEQUENCE TYPING; TREATMENT OUTCOME; UGANDA;

EID: 84954522295     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01299-15     Document Type: Article

References (46)

1. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. 2009. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 23:525-530. http: //dx.doi.org/10.1097/QAD.0b013e328322ffac.
2. Rajasingham R, Meya DB, Boulware DR. 2012. Integrating cryptococcal antigen screening and preemptive treatment into routine HIV care. J Acquir Immune Defic Syndr 59:e85-e91.
3. Brown GD, Denning DW, Gow NA, Levitz SM, Netea MG, White TC. 2012. Hidden killers: human fungal infections. Sci Transl Med 4:165rv13. http://dx.doi.org/10.1126/scitranslmed.3004404.
4. World Health Organization. 2011. Rapid advice: diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children. World Health Organization, Geneva, Switzerland.
5. Day JN, Chau TT, Wolbers M, Mai PP, Dung NT, Mai NH, Phu NH, Nghia HD, Phong ND, Thai CQ. 2013. Combination antifungal therapy for cryptococcal meningitis. N Engl J Med 368:1291-1302. http://dx.doi.org/10.1056/NEJMoa1110404.
6. Gray KC, Palacios DS, Dailey I, Endo MM, Uno BE, Wilcock BC, Burke MD. 2012. Amphotericin primarily kills yeast by simply binding ergosterol. Proc Natl Acad Sci U S A 109:2234-2239. http://dx.doi.org/10.1073 /pnas.1117280109.
7. Odds FC, Brown AJ, Gow NA. 2003. Antifungal agents: mechanisms of action. Trends Microbiol 11:272-279. http://dx.doi.org/10.1016/S0966-842X(03)00117-3.
8. Bicanic T, Meintjes G, Wood R, Hayes M, Rebe K, Bekker L-G, Harrison T. 2007. Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviralexperienced patients treated with amphotericin B or fluconazole. Clin Infect Dis 45:76-80. http://dx.doi.org/10.1086/518607.
9. Brouwer AE, Rajanuwong A, Chierakul W, Griffin GE, Larsen RA, White NJ, Harrison TS. 2004. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomized trial. Lancet 363: 1764-1767. http://dx.doi.org/10.1016/S0140-6736(04)16301-0.
10. Vanden BH, Dromer F, Improvisi I, Lozano-Chiu M, Rex J, Sanglard D. 1998. Antifungal drug resistance in pathogenic fungi. Med Mycol 36:119-128.
11. Rajasingham R, Rolfes MA, Birkenkamp KE, Meya DB, Boulware DR. 2012. Cryptococcal meningitis treatment strategies in resource-limited settings: a cost-effectiveness analysis. PLoS Med 9:e1001316. http://dx.doi.org/10.1371/journal.pmed.1001316.
12. Jarvis JN, Bicanic T, Loyse A, Namarika D, Jackson A, Nussbaum JC, Longley N, Muzoora C, Phulusa J, Taseera K, Kanyembe C, Wilson D, Hosseinipour MC, Brouwer AE, Limmathurotsakul D, White N, van der Horst C, Wood R, Meintjes G, Bradley J, Jaffar S, Harrison T. 2014. Determinants of mortality in a combined cohort of 501 patients with HIV-associated cryptococcal meningitis: implications for improving outcomes. Clin Infect Dis 58:736-745. http://dx.doi.org/10.1093/cid/cit794.
13. Longley N, Muzoora C, Taseera K, Mwesigye J, Rwebembera J, Chakera A, Wall E, Andia I, Jaffar S, Harrison TS. 2008. Dose-response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda. Clin Infect Dis 47:1556-1561. http://dx.doi.org/10.1086/593194.
14. Loyse A, Thangaraj H, Easterbrook P, Ford N, Roy M, Chiller T, Govender N, Harrison TS, Bicanic T. 2013. Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries. Lancet 13:629-637. http://dx.doi.org/10.1016/S1473-3099(13)70078-1.
15. Zhai B, Wu C, Wang L, Sachs MS, Lin X. 2012. The antidepressant sertraline provides a promising therapeutic option for neurotropic cryptococcal infections. Antimicrob Agents Chemother 56:3758-3766. http: //dx.doi.org/10.1128/AAC.00212-12.
16. CLSI. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard - 3rd ed. CLSI document M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
17. CLSI. 2012. Reference method for broth dilution antifungal susceptibility testing of yeasts: fourth informational supplement, CLSI document M27-S4. Clinical and Laboratory Standards Institute, Wayne, PA.
18. Jessup C, Pfaller M, Messer S, Zhang J, Tumberland M, Mbidde E, Ghannoum M. 1998. Fluconazole susceptibility testing of Cryptococcus neoformans: comparison of two broth microdilution methods and clinical correlates among isolates from Ugandan AIDS patients. J Clin Microbiol 36:2874-2876.
19. Pfaller M, Messer S, Boyken L, Hollis R, Rice C, Tendolkar S, Diekema D. 2004. In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn Microbiol Infect Dis 48:201-205. http://dx.doi.org /10.1016/j.diagmicrobio.2003.09.008.
20. Pfaller M, Zhang J, Messer S, Brandt M, Hajjeh R, Jessup C, Tumberland M, Mbidde E, Ghannoum M. 1999. In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa. Antimicrob Agents Chemother 43:169-171. http://dx.doi.org/10.1093/oxfordjournals.jac.a020873.
21. Fothergill A. 2012. Antifungal susceptibility testing: Clinical Laboratory and Standards Institute (CLSI) methods, p 65-74. In Hall G (ed), Interations of yeasts, moulds, and antifungal agents: how to detect resistance. Springer, New York, NY. http://dx.doi.org/10.1007/978-1-59745-135-5-2.
22. Espinel-Ingroff A, Aller A, Canton E, Castañón-Olivares L, Chowdhary A, Cordoba S, Cuenca-Estrella M, Fothergill A, Fuller J, Govender N. 2012. Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole and voriconazole. Antimicrob Agents Chemother 56:5898-5906. http: //dx.doi.org/10.1128/AAC.01115-12.
23. Boulware DR, Meya DB, Muzoora C, Rolfes MA, Huppler Hullsiek K, Musubire A, Taseera K, Nabeta HW, Schutz C, Williams DA, Rajasingham R, Rhein J, Thienemann F, Lo MW, Nielsen K, Bergemann TL, Kambugu A, Manabe YC, Janoff EN, Bohjanen PR, Meintjes G, COAT Trial Team. 2014. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N Engl J Med 370:2487-2498. http://dx.doi.org/10.1056/NEJMoa1312884.
24. Wiesner DL, Moskalenko O, Corcoran JM, McDonald T, Rolfes MA, Meya DB, Kajumbula H, Kambugu A, Bohjanen PR, Knight JF. 2012. Cryptococcal genotype influences immunologic response and human clinical outcome after meningitis. mBio 3:e00196-12. http://dx.doi.org/10.1128/mBio.00196-12.
25. Liu D, Coloe S, Baird R, Pedersen J. 2000. Rapid mini-preparation of fungal DNA for PCR. J Clin Microbiol 38:471-471.
26. Meyer W, Aanensen DM, Boekhout T, Cogliati M, Diaz MR, Esposto MC, Fisher M, Gilgado F, Hagen F, Kaocharoen S. 2009. Consensus multilocus sequence typing scheme for Cryptococcus neoformans and Cryptococcus gattii. Med Mycol 47:561-570. http://dx.doi.org/10.1080 /13693780902953886.
27. Litvintseva AP, Thakur R, Vilgalys R, Mitchell TG. 2006. Multilocus sequence typing reveals three genetic subpopulations of Cryptococcus neoformans var. grubii (serotype A), including a unique population in Botswana. Genetics 172:2223-2238.
28. Lee C-H, Chang T-Y, Liu J-W, Chen F-J, Chien C-C, Tang Y-F, Lu C-H. 2012. Correlation of anti-fungal susceptibility with clinical outcomes in patients with cryptococcal meningitis. BMC Infect Dis 12:361. http://dx.doi.org/10.1186/1471-2334-12-361.
29. Bicanic T, Meintjes G, Rebe K, Williams A, Loyse A, Wood R, Hayes M, Jaffar S, Harrison T. 2009. Immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis: a prospective study. J Acquir Immune Defic Syndr 51:130-134. http://dx.doi.org/10.1097/QAI.0b013e3181a56f2e.
30. Wiesner DL, Boulware DR. 2011. Cryptococcus-related immune reconstitution inflammatory syndrome (IRIS): pathogenesis and its clinical implications. Curr Fungal Infect Rep 5:252-261. http://dx.doi.org/10.1007 /s12281-011-0064-8.
31. Boulware DR, Meya DB, Bergemann TL, Wiesner DL, Rhein J, Musubire A, Lee SJ, Kambugu A, Janoff EN, Bohjanen PR. 2010. Clinical features and serum biomarkers in HIV immune reconstitution inflammatory syndrome after cryptococcal meningitis: a prospective cohort study. PLoS Med 7:e1000384. http://dx.doi.org/10.1371/journal.pmed.1000384.
32. Chang CC, Dorasamy AA, Gosnell BI, Elliott JH, Spelman T, Omarjee S, Naranbhai V, Coovadia Y, Ndung'u T, Moosa MY, Lewin SR, French MA. 2013. Clinical and mycological predictors of cryptococcosisassociated immune reconstitution inflammatory syndrome. AIDS 27: 2089-2099. http://dx.doi.org/10.1097/QAD.0b013e3283614a8d.
33. Aller A, Martin-Mazuelos E, Lozano F, Gomez-Mateos J, Steele-Moore L, Holloway W, Gutierrez M, Recio F, Espinel-Ingroff A. 2000. Correlation of fluconazole MICs with clinical outcome in cryptococcal infection. Antimicrob Agents Chemother 44:1544-1548. http://dx.doi.org/10.1128/AAC.44.6.1544-1548.2000.
34. Witt MD, Lewis RJ, Larsen RA, Milefchik EN, Leal MAE, Haubrich RH, Richie JA, Edwards JE, Ghannoum MA. 1996. Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: the role of antifungal susceptibility testing. Clin Infect Dis 22:322-328. http://dx.doi.org/10.1093/clinids/22.2.322.
35. Gaskell KM, Rothe C, Gnanadurai R, Goodson P, Jassi C, Heyderman RS, Allain TJ, Harrison TS, Lalloo DG, Sloan DJ, Feasey NA. 2014. A prospective study of mortality from cryptococcal meningitis following treatment induction with 1,200 mg oral fluconazole in Blantyre, Malawi. PLoS One 9:e110285. http://dx.doi.org/10.1371/journal.pone.0110285.
36. Meya DB, Manabe YC, Castelnuovo B, Cook BA, Elbireer AM, Kambugu A, Kamya MR, Bohjanen PR, Boulware DR. 2010. Costeffectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count ≤100 cells/μl who start HIV therapy in resource-limited settings. Clin Infect Dis 51:448-455. http://dx.doi.org/10.1086/655143.
37. Verweij PE, Snelders E, Kema GH, Mellado E, Melchers WJ. 2009. Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? Lancet 9:789-795. http://dx.doi.org/10.1016/S1473-3099(09)70265-8.
38. World Factbook. 2008. Uganda. Central Intelligence Agency, Washington, DC.
39. Tushemereirwe W, Kashaija I, Tinzaara W, Nankinga C, New S. 2003. Banana production manual: a guide to successful banana production in Uganda. Makerere University Printery, Kampala, Uganda.
40. Namanda S, Olanya O, Adipala E, Hakiza J, El-Bedewy R, Baghsari A, Ewell P. 2004. Fungicide application and host-resistance for potato late blight management: benefits assessment from on-farm studies in SW Uganda. Crop Protection 23:1075-1083. http://dx.doi.org/10.1016 /j.cropro.2004.03.011.
41. Bailey R, McFarlane S, Singh V, Kumar V. The incidence and effects of ratoon stunting disease of sugarcane in Southern and Central Africa, p 338-346. In Singh V, Kumar V (ed), Proceedings of the XXIII ISSCT Congress, New Delhi, India.
42. Gianessi L, Williams A. 2011. Fungicide spraying is critical for increasing potato production in Africa. CropLife Foundation, Washington, DC.
43. Mukiibi JK. 2001. Agriculture in Uganda. Fountain Publishers, Wageningen, Netherlands.
44. Mulumba J, Nankya R, Adokorach J, Kiwuka C, Fadda C, De Santis P, Jarvis D. 2012. A risk-minimizing argument for traditional crop varietal diversity use to reduce pest and disease damage in agricultural ecosystems of Uganda. Agric Ecosyst Environ 157:70-86. http://dx.doi.org/10.1016/j.agee.2012.02.012.
45. Rutherford MA, Phiri N. 2006. Pests and diseases of coffee in Eastern Africa: a technical and advisory manual. CAB International, Wallingford, Oxon, United Kingdom.
46. Mfinanga S, Chanda D, Kivuyo SL, Guinness L, Bottomley C, Simms V, Chijoka C, Masasi A, Kimaro G, Ngowi B, Kahwa A, Mwaba P, Harrison TS, Egwaga S, Jaffar S, REMSTART trial team. 2015. Cryptococcal meningitis screening and community-based early adherence support in people with advanced HIV infection starting antiretroviral therapy in Tanzania and Zambia: an open-label, randomised controlled trial. Lancet 385:2173-2182. http://dx.doi.org/10.1016/S0140-6736(15)60164-7.